Fig. 2: Patient with bilateral lung lesions at baseline and lung lesion inflammation and localised perilesional oedema on Cycle 1 Day 3.
The patient received 60 mg cibisatamab on Cycle 1 Day 1 and experienced transient hypoxia and transient dyspnoea 48 h after infusion. CT Computed tomography.
